Literature DB >> 25628919

Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics.

Rong Wang1, Xiao-Feng Chen1, Yong-Qian Shu1.   

Abstract

Distant metastasis is one of the most common causes for failure in treatment of advanced NSCLC, and it is a key factor to determine the patients' prognosis. This study aims to screen the microRNAs associated with non-small cell lung cancer metastasis, so as to provide theoretical basis for investigating their roles in non-small cell lung cancer metastasis. In this study, the fluorescent transfected human non-small cell lung cancer cell lines H460 developed tumors subcutaneously, which were then in situ transplanted into the left lung of nude mice to obtain the tissue specimens of primary tumor and metastatic tumor. The differentially expressed microRNAs associated with non-small cell lung cancer metastasis were identified using the microRNA microarray and real-time quantitative polymerase chain reaction (RT-PCR) analysis, and bioinformatics analysis of the microRNAs was performed. The microarray analysis results revealed that 17 microRNAs with up-regulated expression and 7 with down-regulated expression between the non-small cell lung cancer metastatic primary loci and the non-metastatic primary loci (Group A), while 20 microRNAs with up-regulated expression (ratio > 1.5 times, P < 0.05) and 16 with down-regulated expression (ratio < 0.65 times, P < 0.05) between the non-small cell lung cancer metastatic loci and the metastatic primary loci (Group B). RT-PCR validation and bioinformatics analysis of some microRNAs identified 2 microRNAs with up-regulated expression, miR-10b and miR-144, and 3 microRNAs with down-regulated expression, miR-9, miR-31 and miR-34b in Group A; and 4 microRNAs with down-regulated expression, miR-25, miR-92a, miR-202 and miR-326 in Group B, which may be mediated by transcription factors activator protein 1 (AP-1), p53, STATs and NF-κB, regulate cell development, proliferation and cycle, DNA and RNA metabolism and signal transduction pathway, and promote tumor growth and metastasis through the effects on target genes like RARβ, RASSF1 and E2F-1. In conclusion, there are differences in microRNA expression between the non-small cell lung cancer metastatic and non-metastatic tissues, which provides experimental basis for exploring the mechanism of non-small cell lung cancer metastasis and provides a potential idea for molecular diagnosis and treatment, as well as prognosis.

Entities:  

Keywords:  Non-small cell lung cancer; metastasis; microRNA; microarray; nude mouse model; target gene

Year:  2014        PMID: 25628919      PMCID: PMC4300719     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  41 in total

Review 1.  The tumor suppressor RASSF1A in human carcinogenesis: an update.

Authors:  R Dammann; U Schagdarsurengin; C Seidel; M Strunnikova; M Rastetter; K Baier; G P Pfeifer
Journal:  Histol Histopathol       Date:  2005-04       Impact factor: 2.303

2.  miR-592 and miR-552 can distinguish between primary lung adenocarcinoma and colorectal cancer metastases in the lung.

Authors:  Hark Kyun Kim; Na Jung Lim; Sang-Geun Jang; Geon Kook Lee
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

3.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

4.  Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer.

Authors:  He Zhu; Feriyl Bhaijee; Nivin Ishaq; Dominique J Pepper; Kandis Backus; Alexandra S Brown; Xinchun Zhou; Lucio Miele
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

5.  Distinct regulatory mechanisms of the human ferritin gene by hypoxia and hypoxia mimetic cobalt chloride at the transcriptional and post-transcriptional levels.

Authors:  Bo-Wen Huang; Masaki Miyazawa; Yoshiaki Tsuji
Journal:  Cell Signal       Date:  2014-08-27       Impact factor: 4.315

6.  Tumor suppressor TSLC1 inhibits growth, proliferation, invasiveness and angiogenesis in nude mice xenografted tumor of Eca109 cells.

Authors:  Qi-Lian Liang; Guo-Qiang Chen; Qiu-Long Liu; Zhou-Yu Li; Xiang-Ning Zhang; Yuan Zhou; Wen-Ting Ou; Bi-Rong Wang; Li-Ren Hu
Journal:  Int J Clin Exp Med       Date:  2014-06-15

7.  Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.

Authors:  Hongyan Ying; Xian-Da Yang; Zhao Sun; Xiaohong Ning; Yingyi Wang; Chunmai Bai; Shuchang Chen; Yuzhou Wang
Journal:  Med Oncol       Date:  2014-09-13       Impact factor: 3.064

8.  Vascular development in mouse lung metastases.

Authors:  Howard W Salmon; Ananya Guha; Amyn M Rojiani; Dietmar W Siemann
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

9.  Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer.

Authors:  Wei Liao; Gwen Jordaan; Minu K Srivastava; Steven Dubinett; Sherven Sharma; Sanjai Sharma
Journal:  Am J Cancer Res       Date:  2013-08-14       Impact factor: 6.166

10.  TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis.

Authors:  L Larzabal; A L de Aberasturi; M Redrado; P Rueda; M J Rodriguez; M E Bodegas; L M Montuenga; A Calvo
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

View more
  22 in total

Review 1.  The fundamental role of miR-10b in metastatic cancer.

Authors:  Patrick Sheedy; Zdravka Medarova
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

2.  MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1.

Authors:  Yun Liu; Xu Hu; Daokui Xia; Songlin Zhang
Journal:  Oncol Lett       Date:  2016-09-28       Impact factor: 2.967

3.  Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum.

Authors:  Jinghua Zhu; Yuhua Qi; Jianzhong Wu; Meiqi Shi; Jifeng Feng; Longbang Chen
Journal:  Oncol Lett       Date:  2016-10-19       Impact factor: 2.967

4.  Exosomal miRNAs as biomarkers of recurrent lung cancer.

Authors:  Radha Munagala; Farrukh Aqil; Ramesh C Gupta
Journal:  Tumour Biol       Date:  2016-02-11

5.  LncARSR promotes non-small-cell lung cancer progression via regulating PTEN/Akt.

Authors:  Jie Ying; Jian Yang; Yingzi Liu
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

6.  MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR.

Authors:  Rong Wang; Xiaofeng Chen; Tongpeng Xu; Rui Xia; Liang Han; Wenming Chen; Wei De; Yongqian Shu
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

7.  MicroRNA-133a downregulated EGFR expression in human non-small cell lung cancer cells via AKT/ERK signaling.

Authors:  Nannan Guo; Yingnan Zhao; Wen Zhang; Shaojun Li; Shanshan Li; Jianqi Yu
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

8.  LncRNA SNHG3 Promotes Gastric Cancer Cells Proliferation, Migration, and Invasion by Targeting miR-326.

Authors:  Jun Rao; Jinjin Fu; Chuchen Meng; Jin Huang; Xiangrong Qin; Shaohua Zhuang
Journal:  J Oncol       Date:  2021-06-28       Impact factor: 4.501

9.  Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development.

Authors:  Chengcao Sun; Chuanfeng Huang; Shujun Li; Cuili Yang; Yongyong Xi; Liang Wang; Feng Zhang; Yunfeng Fu; Dejia Li
Journal:  Oncotarget       Date:  2016-02-16

10.  Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling.

Authors:  Hua Shen; Xiaobo Yu; Fengming Yang; Zhihua Zhang; Jianxin Shen; Jin Sun; Swati Choksi; Siriporn Jitkaew; Yongqian Shu
Journal:  PLoS Genet       Date:  2016-08-19       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.